Pharsight

Janumet patents expiration

JANUMET's oppositions filed in EPO
JANUMET IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MSD SUB MERCK Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7125873 MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7125873

(Pediatric)

MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 4 months ago)

US6699871

(Pediatric)

MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 4 months ago)

US7326708

(Pediatric)

MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)

US8414921 MSD SUB MERCK Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(4 years from now)

US8414921

(Pediatric)

MSD SUB MERCK Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jan, 2029

(4 years from now)

Janumet is owned by Msd Sub Merck.

Janumet contains Metformin Hydrochloride; Sitagliptin Phosphate.

Janumet has a total of 12 drug patents out of which 8 drug patents have expired.

Expired drug patents of Janumet are:

  • US6303661
  • US6890898
  • US7459428
  • US7078381
  • US7125873
  • US6699871
  • US7125873*PED
  • US6699871*PED

Janumet was authorised for market use on 30 March, 2007.

Janumet is available in tablet;oral dosage forms.

Janumet can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.

Drug patent challenges can be filed against Janumet from 05 June, 2023.

The generics of Janumet are possible to be released after 21 January, 2029.

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage

JANUMET family patents

Family Patents